Protara Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Protara Therapeutics

01/08/2025 15:17

Protara Therapeutics Inc TARA.OQ TARA.O is expected to  show no change in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Protara Therapeutics Inc is for a loss of 40 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Protara Therapeutics Inc is $22.50, about 86.2% above its last closing price of $3.10

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.40
-0.45
-0.29
Beat
35.8
Dec. 31 2025
-0.56
-0.56
-0.49
Beat
13.3
Sep. 30 2024
-0.52
-0.52
-0.50
Beat
3.8​
Jun. 30 2024
-0.96
-0.80
-0.45
Beat
43.8
​​Mar. 31 2024
-0.86
-0.92
-0.97
Missed
-5.4
Dec. 31 2023
-0.92
-0.90
Beat
1.9​
Sep. 30 2023
-1.04
-0.98
-0.87
Beat
11.2
Jun. 30 2023
-0.88
-0.87
-1.00
Missed
-14.3

This summary was machine generated August 1 at 14:17 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)